Subscribe to RSS
DOI: 10.1055/s-0030-1267516
© Georg Thieme Verlag KG Stuttgart · New York
Neue Antikoagulanzien für die Thromboembolieprophylaxe bei Vorhofflimmern
Novel anticoagulants for stroke prevention in atrial fibrillationPublication History
eingereicht: 26.7.2010
akzeptiert: 21.10.2010
Publication Date:
09 November 2010 (online)
Zusammenfassung
Vorhofflimmern ist die häufigste Herzrhythmusstörung und Hauptursache für kardioembolische Schlaganfälle. Die Thromboembolieprophylaxe erfolgt in Abhängigkeit des individuellen Risikos mit Acetylsalicylsäure (ASS) oder Vitamin-K-Antagonisten. Die Effektivität und Sicherheit der oralen Antikoagulation wird durch eine enge therapeutische Breite und inter- und intraindividuellen Schwankungen des INR-Wertes aufgrund genetischer Dispositionen sowie alimentärer Einflüsse, Dosierungsfehler, zu seltene INR-Kontrolle und Arzneimittelinteraktionen beträchtlich limitiert. Neue, oral verfügbare Substanzen mit unterschiedlichen Wirkmechanismen stellen vielversprechende Therapiealternativen dar. In dieser Arbeit werden die Faktor-Xa-Inhibitoren Apixaban, Rivaroxaban, der direkte Thrombininhibitor Dabigatranetexilat mit ihren korrespondierenden Phase-III-Studien (ARISTOTLE, ROCKET-AF, RE-LY) bei Patienten mit Vorhofflimmern näher erläutert und das Studiendesign und – soweit verfügbar – auch die Studienergebnisse verglichen.
Abstract
The most frequent cardiac arrhythmia and main cause for cardio-embolic stroke is atrial fibrillation. Prophylaxis for thrombembolic events is performed regarding individual risk of patients with either ASS or vitamin-K-antagonists. Efficacy and safety of oral anticoagulation is limited by a narrow therapeutical range as well as by inter- and intraindividual variability of INR-values due to genetic disposition, differences in alimentation, dosage errors, rare control of INR-levels and drug-interactions. New oral anticoagulants with different mechanisms of action may be a promising therapeutic option in future. This review addresses the new anticoagulants Apixaban, Rivaroxban and Dabigatranetexilat with the design and as available the results of the corresponding phase-III-trials in atrial fibrillation (ARISTOTLE, ROCKET-AF, RE-LY).
Schlüsselwörter
Dabigatran - Rivaroxaban - Apixaban - orale Antikoagulation - Vorhofflimmern
Keywords
dabigatran - rivaroxaban - apixaban - oral anticoagulation - atrial fibrillation
Literatur
- 1 Ansell J, Hollowell J, Pengo V. et al . Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis. 2007; 23 83-91
- 2 Connolly S J, Ezekowitz M D, Yusuf S. et al . Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009; 361 1139-1151
- 3 Diener H C. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006; 21 279-293
- 4 Eikelboom J W, O’Donnell M, Yusuf S. et al . Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010; 159 348-353 e341
- 5 Fetsch T, Bauer P, Engberding R. et al . Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European heart journal. 2004; 25 1385-1394
- 6 Fuster V, Ryden L E, Cannom D S. et al . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – excutive summary. Rev Port Cardiol. 2007; 26 383-446
- 7 Goto S, Bhatt D L, Rother J. et al . Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008; 156 855-863, 863 e852
- 8 Grau A J, Weimar C, Buggle F. et al . Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001; 32 2559-2566
- 9 Group SRiAFW . Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69 546-554
- 10 Hankey G J, Eikelboom J W. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 2010; 9 273-284
- 11 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146 857-867
- 12 Hylek E M, Evans-Molina C, Shea C, Henault L E, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007; 115 2689-2696
- 13 Kirchhof P, Bax J, Blomstrom-Lundquist C. et al . Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J. 2009; 30 2969-2977c
- 14 Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008; 24 2757-2765
- 15 Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59 – 7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78 412-421
- 16 Lin H J, Wolf P A, Kelly-Hayes M. et al . Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27 1760-1764
- 17 Lopes R D, Alexander J H, Al-Khatib S M. et al . Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010; 159 331-339
- 18 Mann K G, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost. 2003; 1 1504-1514
- 19 Miyasaka Y, Barnes M E, Gersh B J. et al . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114 119-125
- 20 Rother J, Laufs U. Prävention des Schlaganfalls durch Behandlung des Vorhofflimmerns. Dtsch Med Wochenschr. 2010; 135 Suppl 2 S55-58
- 21 Sherman D G. Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm control. Stroke. 2007; 38 615-617
- 22 Singer D E, Albers G W, Dalen J E. et al . Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 33 546S-592S
- 23 van Ryn J, Stangier J, Haertter S. et al . Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 03 1116-1127
- 24 van Walraven C, Jennings A, Oake N, Fergusson D, Forster A J. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006; 29 1155-1166
- 25 Zhang D, He K, Raghavan N. et al . Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009; 37 1738-1748
Dr. Magnus Baumhäkel
Klinik für Innere Medizin III
Universitätsklinikum
des Saarlandes
66421 Homburg/Saar
Phone: 06841/1623289
Fax: 06841/1623446
Email: magnus@baumhaekel.de